Povorcitinib

5 trials 2 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

1 Sponsors

13 Countries

Phase III

Phase II

Phase III: 3 Phase II: 2

Indications tested

Vitiligo 3 Asthma 1 Chronic spontaneous urticaria 1

Sponsors using this IMP

All trials

5 total

Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Phase III 13 countries Incyte Corp.
A Study Evaluating the Efficacy and Safety of Povorcitinib (INCB054707) in Adults With Inadequately Controlled Moderate to Severe Asthma Recruiting

2022-502570-16-01 Phase II 3 countries Incyte Corp.
Selective Treatment of Oral Povorcitinib in Vitiligo Study 1 (STOP-V1) Ended

2023-505782-86-00 Phase III 6 countries Incyte Corp.
Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended

2023-506011-18-00 Phase III 6 countries Incyte Corp.
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended

2022-503062-72-00 Phase II 2 countries Incyte Corp.

Showing 1–5 of 5 trials

← All drugs A–Z